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Abstract
Background & Aims—There is no histologic classification system to determine prognoses of
patients with alcoholic hepatitis (AH). We identified histologic features associated with disease
severity and created a histologic scoring system to predict short-term (90 day) mortality.
Methods—We analyzed data from 121 patients admitted to the Liver Unit (Hospital Clinic,
Barcelona, Spain) from January 2000 through January 2008 with features of AH, and developed a
histologic scoring system to determine risk of death using logistic regression. The system was
tested and updated in a test set of 96 patients from 5 academic centers in the US and Europe, and a
semi-quantitative scoring system was developed, called the alcoholic hepatitis histologic score
(AHHS). The system was validated in an independent set of 109 patients. Inter-observer
agreement was evaluated by weighted statistic analysis.
Results—Degree of fibrosis, neutrophil infiltration, type of bilirubinostasis, and presence mega-
mitochondria were independently associated with 90 day mortality. We used these 4 parameters to
develop the AHHS to identify patients with low (0–3 points), moderate (4–5 points), and high (6–
9 points) risks of death within 90 days (3%, 19%, and 51%, respectively; P<.0001). The AHHS
estimated 90 day mortality in the training and test sets with an area under the receiver operating
characteristic value of 0.77 (95% confidence interval, 0.71–0.83). Inter-rate agreement values
were 0.65 for fibrosis, 0.86 for bilirubinostasis, 0.60 for neutrophil infiltration, and 0.46 for
megamitochondria. Interestingly, the type of bilirubinostasis predicted the development of
bacterial infections.
Conclusions—We identified histologic features associated with severity of AH and developed a
patient classification system that might be used in clinical decision making.
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Alcoholic hepatitis (AH) is the most severe form of alcoholic liver disease (1). In its most
severe form, short-term mortality of AH remains high (20–30%) probably due to poor
patient characterization and the need for modern targeted therapies (2). Current therapies
(i.e. corticosteroids and pentoxifylline) fail in many patients and there is a clear need to
develop new pathophysiologically-oriented approaches. Although the presence of AH can be
suspected based on clinical and biochemical data, a definitive diagnosis requires histological
confirmation (3). Regretfully, there are no well-validated non-invasive methods to establish
the diagnosis of AH.
In contrast to the huge burden of alcoholic liver disease and the prevalence of AH, the
research investment into this disease has been limited (4). Although prognosis can be
estimated based on biochemical parameters (2, 5–7), AH is probably the only prevalent liver
disease that lacks a well-validated histological classification that can provide both
prognostic and clinically meaningful data. Identifying key histological parameters associated
with patient outcome can inform translational studies and also reveal key disease drivers.
Histological classification schemes exist for other prevalent liver diseases such as chronic
viral hepatitis, non-alcoholic steatohepatitis, autoimmune hepatitis and primary biliary
cirrhosis (8–12). The present study attempts to fill an important gap in the field of AH. We
performed a large multicentric study, including some of the main experts in this field, to
develop a novel histological classification. Study, testing, and validation cohorts of patients
with biopsy proven AH were included.
There are some reports showing that isolated histological findings can reflect disease
severity in patients with AH (13–17). However, no studies have integrated these parameters
to develop a meaningful histological classification. Thus, the aims of this study were to
investigate how the interaction of individual histological features of AH predicts survival,
and if it can be used to generate and validate a novel histological scoring system.
METHODS
Study Cohort
One hundred and eighty one consecutive patients admitted to the Liver Unit (Hospital
Clinic, Barcelona, Spain) from January 2000 to January 2008 with clinical and analytical
parameters suggesting an episode of AH were studied. The inclusion criteria were: excessive
alcohol consumption (>60 g/day) prior to admission, moderately elevated aminotransferases
with aspartate aminotransferase [AST] > alanine aminotransferase [ALT], high -glutamyl
transpeptidase (GGT) and serum bilirubin levels, and a histological diagnosis of AH
characterized by the presence of hepatocellular damage (hepatocellular ballooning and
presence of Mallory bodies), inflammatory infiltrate (predominantly polymorphonuclear
cells), and pericellular fibrosis (2,18). All patient that gave an informed consent underwent a
liver biopsy within 48 hours of admission as part of our clinical protocol. Sixty patients were
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not included due to other causes of liver disease (concomitant hepatitis C virus n=16,
concomitant hepatitis C virus/HIV co-infection n=3, drug-induced hepatotoxicity n=4,
hemochromatosis n=1, military tuberculosis n=1 and syphilitic hepatitis n=1) or incomplete
histological criteria of AH (n=34). After histological confirmation and a strict evaluation of
inclusion and exclusion criteria, 121 patients with biopsy-proven AH were included and
conformed the training set.
Severe AH was defined as a Maddrey’s discriminant function >32 and/or an ABIC score
≥6.71 at admission (2). Patients with Maddrey’s discriminant function >32 were treated with
prednisone orally for 4 weeks followed by a 2 weeks taper period. During hospitalization,
patients with clinical complications such as ascites, spontaneous bacterial peritonitis, renal
dysfunction, overt hepatic encephalopathy (HE) or gastrointestinal bleeding associated with
portal hypertension were treated according to current international guidelines (19–22). The
Ethics Committee of the Hospital Clinic Barcelona approved the study and all patients gave
written informed consent.
Histological, Clinical and Hemodynamic Assessment
Demographic, clinical, and analytic parameters were collected for creation of a
comprehensive database as described previously (2, 23). The response to corticosteroid
treatment was assessed at 7 days using the Lille Model (24). All liver biopsies in the training
set were obtained by transjugular approach within 48 hours of admission. Liver specimens
(LS) were formalin-fixed and paraffin-embedded, and slides of 3 μm were stained with
hematoxylin-eosin and Masson’s trichrome. An expert liver pathologist reviewed all
biopsies (R.M.) and was blinded. A detailed histological analysis was prospectively
performed as follows: (a) degree of hepatocellular damage/ballooning (0=mild and
1=marked), (b) presence of Mallory bodies (0=absent and 1=present), (c) degree of
polymorphonuclear (PMN) infiltration (0=mild and 1= moderate/severe), (d) degree of
steatosis (0 = <33%, 1 = 33 – 66%, 2 = >66%), (e) lobular fibrosis (0=no fibrosis or zone 3,
1=fibrosis in zone 2+3 and 2=panlobular fibrosis), (f) fibrosis stage (0=no fibrosis or portal
fibrosis, 1= expansive periportal fibrosis, 2= bridging fibrosis and cirrhosis), (g)
megamitochondria (0=no, 1=yes) and (h) presence and site of bilirubinostasis (0=none,
1=hepatocellular bilirubinostasis, 2=canalicular or ductular bilirubinostasis,
3=hepatocellular + canalicular or ductular bilirubinostasis) (25). See Supplementary Data
for detailed explanation of histological evaluation. Hepatic hemodynamic assessment was
performed within 48 h of admission. The portal pressure was estimated based on the HVPG,
as described in detail previously (26).
Test and Validation Sets
Five international academic centers contributed 205 consecutive additional patients with
alcoholic hepatitis (University Hospital Gasthuisberg, KU Leuven, Belgium; Mayo Clinic,
Rochester, MN; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Hôpital
Huriez, Lille, France and Royal Free Hospital, London, UK). These patients constituted the
test set and validation cohort (see details in Supplementary Methods). All participant centers
followed the same inclusion/exclusion criteria outlined above for the training set. In all of
these centers, the vast majority of biopsies were performed within 48 h from admission and
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were processed and analyzed in the same way as in the training set (see Statistical Analysis
for details).
The histological assessment of liver specimens was performed by expert liver pathologists.
LS from Lille (France) were fixed with alcohol-formalin-acetic acid, the rest of LS where
fixed as in the study cohort. Importantly, to ensure a homogeneous histological assessment
of all biopsies, a detailed training plan was carried out between the central pathologist
(R.M.) and all local pathologists, including teleconferences and presentations describing all
histological parameters. To establish an inter-observer agreement between the central
pathologist with other participant centers, 71 slide-kits were cross-shared for histological
interpretation to determine a kappa coefficient.
Statistical Analysis
Continuous variables were described as means (95% confidence interval) or medians
(interquartile range). Categorical variables were described by means of counts and
percentages. Comparisons between groups were performed using the Student’s t test or the
Mann-Whitney U test when appropriate. Differences between categorical variables were
assessed by the chi-square test or the Fisher exact test. The main endpoint was death at 90
days. Other endpoints were development of clinical complications during hospitalization
(i.e. infection) and response to corticosteroids at 7 days.
The initial model was developed in the training set. All histological data were included in
the univariate analysis. A logistic regression univariate analysis was used to identify
histological features associated with 90-day mortality. Variables that were statistically
significant in the univariate model were included in the multivariate logistic regression
model and eliminated using backward stepwise elimination. The criterion for retaining
predictors was a p value <0.10. The performance of this model was evaluated in the test set
and the model was updated by re-estimating the regression coefficients in the training/test
set (study cohort). Of note, no further variable selection was performed at this stage. The
final coefficients were corrected for optimism with bootstrapping. Finally, the model was
converted into a weighted semi-quantitative histological score. At this point the model was
“locked”. See Supplementary Methods for a detailed explanation of model building.
Survival curves were constructed with the Kaplan-Meier method and comparisons were
performed using the log-rank test. Calibration of the model in the validation set was assessed
by plotting predicted vs observed rate of events (27).
Finally, for inter-observer agreement analysis we determined the kappa coefficient and the
weighted kappa coefficient for histological items with multiple categories. To assess if
adding analytical variables to the AHHS could improve the prognostic capability for 90-day
mortality in patients with AH we conducted a multivariable logistic regression analysis as
follows: AHHS was forced into the model in a first block and clinical variables at admission
(e.g. bilirubin, creatinine, age and INR) were included in a second block, and a backwards
selection was performed.
Statistical analysis was performed using the SPSS version 12.0 for Windows (SPSS, Inc.,
Chicago, IL), except for the comparison between ROC curves (concordance [c] statistic
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test), which was performed by the method of Hanley and McNeil using the MedCalc version
9.3.0.0. (Medisoftware, Mariakerke, Belgium) and the kappa analysis which was performed
using the Vassar Stats statistical computation website (http://vassarstats.net/).
RESULTS
Characteristics of the Training Set
The demographic, clinical, analytical, hemodynamic and histological data of the training set
are shown in Table 1. Complications during hospitalization included: 47 (39%) patients
developed a bacterial infection, 22 (18%) patients developed renal failure, 21 (17%) patients
had gastrointestinal bleeding and 38 (31%) patients had an episode of overt HE. Type of
infections during hospitalization were as follows: pulmonary (26%), urinary tract (23%),
soft tissue (8%), spontaneous bacterial peritonitis (6%), catheter related infections (6%),
meningitis (4%) and others (26%). The overall 90-day mortality rate was 29%. The main
causes of death at 90 days were sepsis (29%) and multi-organ failure (52%). The presence of
AH was confirmed histologically in all patients. The prevalence of different histological
findings is shown in Table 1.
Histological Factors Associated with 90-day Survival and Generation of the AHHS score
We first assessed the association between histological features and short-term survival in the
training set. The univariate analysis identified 4 histological features at admission that were
significantly associated with 90-day survival. In the multivariate analysis, fibrosis stage,
PMN infiltration, type of bilirubinostasis, and presence of megamitochondria independently
predicted 90-day survival (Table 2). Of note, the presence of a marked PMN infiltration and
presence of megamitochondria were independently associated with a favorable outcome
(OR=0.13, 95% CI −0.03–0.47- and OR=0.12, 95% CI −0.04–0.36-, respectively). In
contrast, the presence of hepatocellular damage (e.g. Mallory-Denk bodies or hepatocyte
ballooning) and the presence/degree of steatosis did not influence short-term prognosis.
Representative pictures of the histological features independently associated with 90-day
survival are shown in Figure 1 and Figure 2.
The AHHS was generated using the 4 histological features that independently predicted
short-term survival as detailed in Supplementary Methods. The final semi-quantitative score
is shown in Table 3. Optimal cutoff values to define different severity categories were: 3 and
6 points (sensitivity of 98%, 72% and specificity of 20%, 75%, respectively). Using these
cutoff values AHHS identified patients with AH with low, moderate, and high 90-day
mortality rate. Thirty patients (14%) had ≤3 points, 80 patients (37%) had 4–5 points, and
107 patients (49%) had >5 points. As shown in Figure 3a, these cutoff values strongly
discriminate patients with low (97% survival), intermediate (81% survival), and high risk
(49% survival) of death (Linear Log Rank Test: p< .0001), which define patients with mild,
moderate and severe AH.
As expected, patients with severe AHHS had a higher rate of life-threating complications
(e.g. bacterial infections and renal failure) during hospitalization than patients with moderate
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and mild AHHS (30% vs 58% of patients, respectively; p=.005) In patients with severe
AHHS, sepsis was the main cause of death.
We next explored whether the AHHS is also useful in stratifying patients treated with
corticosteroids (n=54). When including patients with severe AH treated with corticosteroids,
we found that the AHHS accurately stratifies patients into 2 subgroups with different
survival at 90 days (85% vs 51%, respectively; p=.05; Supplementary Figure 1).
We finally studied whether the initial AHHS is useful to predict the response to
corticosteroids as defined using the Lille Model. We found that patients with a Lille Model
below 0.45 (responders to corticosteroids) had the same AHHS than patients with a Lille
Model ≥ 0.45 (non-responders to corticosteroids) (5.2 ± 2.0 vs. 6.0 ± 2.0, respectively; p=.
2). Additionally, we found that none of the individual histological features assessed by
AHHS were able to predict the response to corticosteroids at 7 days in these patients.
Therefore, histological findings were not useful to predict the response to corticosteroids
(Supplementary Table 1).
Validation of the Alcoholic Hepatitis Histological Score (AHHS)
The baseline characteristics of the test and validation set (n= 205) are shown in
Supplementary Table 2. Although patients in the external cohorts presented with higher
bilirubin levels, MELD and ABIC scores, 90-day survival was comparable with that of the
study cohort (69% vs. 71%, respectively; p=.7). AHHS demonstrated a robust prognostic
capability to discriminate into three categories with different outcome at 90 days. AHHS
adequately stratified patients with low (0–3 points), moderate (4–5 points) and high (6–9
points) risk of death at 90-days (100%, 83% and 64%survival, respectively; p=.008. Figure
3b). Comparison between predicted and observed mortalities in the validation cohort is
shown in Supplementary Figure 2.
Importantly, we performed a cross sharing of 71 slide-kits for assessing inter-observer
agreement in order to evaluate the reproducibility of the AHHS between our central
pathologist and the liver pathologists of participant centers. Analysis of agreement on
histological features evaluated by the AHHS showed a moderate agreement for the presence
of megamitochondria (K=0.46, 95% CI: 0.27–0.65), good agreement for fibrosis stage and
PMN infiltration (K=0.65, 95% CI:0.36–0.94 and K=0.60, 95% CI:0.42–0.78, respectively)
and an optimal agreement for the scoring of type of bilirubinostasis with weighted-kappa
values of 0.86 (CI 95%:0.75–0.97). The kappa value for the optimized AHHS was 0.64 (CI
95%:0.53–0.80).
Histological parameters associated with bacterial infections
Bacterial infection is one of the main causes of death among patients with AH (28). The
development of diagnostic tools capable of identifying patients with early or “occult”
bacterial infections will help improve management of these patients. Thus, we analyzed if
any of the histological features evaluated by the AHHS were associated with the
development of bacterial infections during hospitalization (developed after 48 h of
admission). The multivariate analysis identified the type of bilirubinostasis (OR 1.57 95%
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CI: 1.00–2.47; p=.04) as the only histological feature associated with the development of
bacterial infections during hospitalization (Supplementary Table 3). Nearly half of the
patients with canalicular/ductular bilirubinostasis or hepatocellular plus canalicular/ductular
bilirubinostasis (46% and 47%, respectively) developed a bacterial infection during
hospitalization (Supplementary Figure 3). Interestingly, we found that increasing levels of
serum bilirubin correlated with the progressive degree of bilirubinostasis (Supplementary
Figure 4).
Prognostic assessment by combining AHHS with analytical data and sequential use of
analytical scoring systems and AHHS
To evaluate the independent prognostic weight between the AHHS and well-validated
scoring systems for AH (e.g. MELD and ABIC scores), a one-step bivariate analysis model
including both scores was fitted. We found that AHHS was independently associated with
90-day survival in both the study and validation cohorts (Supplementary Table 4). Next, we
studied if adding analytical variables to the AHHS could improve the prognostic capability
for 90-day mortality in patients with AH in the training set. We conducted a multivariable
logistic regression analysis as detailed in methods. As shown in Supplementary Table 5,
INR (p=.02), age (p=.003) and bilirubin at admission (p=.04) were the 3 variables with
statistical significance in the presence of AHHS. This model combining AHHS and clinical
variables had an AUROC of 0.89 (CI 95%: 0.84–0.95) to predict 90-day survival.
Additionally, a side-by-side comparison between AHHS and the existing prognostic scores
(MELD and ABIC score) was performed in the complete cohort (n=326). The resulting
AUROCs were: MELD (0.70), ABIC (0.79) and AHHS (0.73). We did not find significant
differences when comparing the AUROCs (AHHS vs MELD: p=0.40 and AHHS vs ABIC:
p=0.15. Supplementary Figure 5). Finally, we studied if the sequential use of analytical and
histological scores could improve the prognostic assessment of patients with AH. The
AHHS did not improve the prognostic assessment in patients with ABIC class A or class C.
However, when including patients belonging to ABIC class B, the AHHS was able to
discriminate patients into two different risks: patients with low (95% survival) and moderate
risk (70% survival) of death at 90 days (p =.003; Figure 4a). When analyzing patients with
MELD score ≤21, the AHHS was able to discriminate two different rates of 90-day survival
(94% vs 72%; p=.001; Figure 4b). We found differences in MELD score between patients
with AHHS≤ 5 and patients with AHHS ≥ 5 points (16 ± 8 vs. 23 ± 9 points of MELD,
respectively; p<.0001. Supplementary Figure 6). These results suggest that the severity of
histological abnormalities is reflected by the analytical parameters present in the MELD
score (e.g. bilirubin).
Finally, in order to study prognostic relevance of HVPG either by itself or in combination
with the AHHS, we compared the mean HVPG in patients who survived and compared to
those who were deceased at 90 days. HVPG was only slightly lower among survivors vs.
deceased patients (18.5±6.1 vs. 20.8±6.4 mmHg, respectively, p=.06. data not shown). To
analyze if HVPG adds prognostic value to AHHS, both variables were included in a logistic
regression analysis. HVPG did not show statistical significance (OR:1.08, 95% CI: 0.99–
1.17; p=.06, data not shown). Finally, no differences in HVPG measurements were found
between patients with definitive AHHS ≥5 and definitive AHHS <5 points (19.0±6 vs.
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19.7±6 mmHg, respectively, p=.3; Supplementary Figure 7). Overall, these results suggest
that HVPG measurement is not useful to increase the prognostic performance of AHHS.
DISCUSSION
The current study has developed a novel histological scoring system capable of predicting
short-term survival in patients with AH. Although previous isolated reports had suggested a
relationship between single histological parameters and disease outcome (13–17), this is the
first systematic investigation including both a study and validation cohort that generates a
prognostic histological classification. Such a classification was lacking in the field of AH
and can be very useful in stratifying patients for clinical trials, in identifying key disease
drivers and to better characterize this devastating disease. Our study was performed in 6
international academic centers from Europe and US and includes 326 patients with biopsy-
proven AH. Importantly, we performed an extensive measurement of inter-observer
agreement, which was lacking for this disease. Our study also defines consistent diagnostic
criteria of the main histological findings that define AH. These criteria can be useful to
define the parameters that need to be evaluated in the histological assessment of AH.
The stage of fibrosis was identified as an independent predictor of short-term mortality in
these patients. This finding is not surprising, given that extensive fibrosis leads to portal
hypertension and favors related complications (17). In fact, the degree of portal hypertension
has been shown to identify patients with AH and poor outcome (29). In our study, we found
that the presence of bridging fibrosis and cirrhosis are associated with poor outcome.
Besides increasing the intrahepatic resistance to blood flow, extensive fibrosis suggests
more severe underlying liver disease and a poor regenerative response to acute-on-chronic
injury. Further studies should investigate the molecular drivers of fibrosis in patients with
AH and whether anti-fibrogenic agents have beneficial effects in these patients.
A striking finding of our study is that the presence and type of bilirubinostasis has a marked
influence in short-term mortality. In fact, AH is analytically characterized by profound
cholestasis and serum bilirubin levels are one of the most powerful predictors of poor
outcome in these patients (2,5,7). Our results confirm previous studies suggesting that
bilirubinostasis is one of the most ominous findings in patients with AH(15–16). The
presence of bilirubinostasis may reflect both poor hepatocellular bile transport and
difficulties with hepatic bile flow. Ballooned hepatocytes have impaired bile salt secretion
and the serum concentration of bile salts is particularly increased in patients with severe AH
(30). Further studies should identify the main molecular drivers of cholestasis in AH and
identify therapeutic targets. Interestingly, the presence of bilirubinostasis was associated
with the development of bacterial infection and sepsis, which typically cause cholestasis. It
is likely that bilirubinostasis reflects poor hepatocellular function which favors bacterial
infections and, in turn, bacterial products worsen biliary secretion. In fact,
lipopolysaccharide (an important bacterial mediator that is markedly increased in AH)
down-regulates bile transporters in hepatocytes and causes cholestasis (31–32).
The finding that PMN infiltration and the presence of megamitochondria identifies patients
with better outcome confirms previous observations (13–14). Several potential reasons
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potentially explain why the presence of severe PMN infiltration is associated with good
outcome. First, patients with more advanced forms of AH are characterized by poor
regenerative response (33) and therefore those presenting with active inflammation may
reflect an earlier or less advanced stage of the disease. Second, inflammatory cells, including
PMNs, secrete cytokines that stimulate liver regeneration (34). Also, the development of
megamitochondria may represent an early stage in hepatocellular damage and has been
shown to be associated with a more favorable outcome (14,35). Whether megamitochondria
is associated with molecular events that protect hepatocytes from cell death is unknown and
deserves further investigation.
The results of our study and the generated AHHS may have important clinical applications.
First, the AHHS represents an independent novel tool for prognostic classification in these
patients. Identification of patients with different outcome is essential for clinical decision-
making and to design clinical trials. Of interest, the AHHS allows a more accurate
prediction of survival of patients with ABIC class B (moderate risk of death – 25% of
overall mortality), leading to more refined prognostic stratification of these patients. In
addition, the AHHS was able to refine the prognostic stratification of patients with MELD
<21 which are traditionally considered to have a low risk of death (7). In the present study
overall mortality of patients with MELD <21 was 20.5% at 90 days. Using a cut-off of 5
points the AHHS was able to define 2 subgroups with different 90-day survival (94% vs
72%). This observation is important since the use of AHHS could stratify patients with a
higher risk of mortality among those initially considered low risk. Thus, the sequential use
of the ABIC or MELD and AHHS systems allows for precise prognostic assessment of
patients with AH with moderate and low risk of death. Second, we identified bilirubinostasis
as a useful predictor of infections. This finding should promote clinicians to rule out
ongoing infections. Whether the presence of bilirubinostasis by itself justifies the
administration of empiric antibiotics is debatable and deserves further study. Finally, by
identifying histological parameters leading to increased mortality (ie. extensive fibrosis and
bilirubinostasis) we have identified key events that influence disease severity which will
certainly help guide development of more accurate animal models of this disease, in order to
perform reliable preclinical studies.
It is important to emphasize that the relevance of our novel histological score is not only
based on its capability to predict survival. In addition to prognostication, our study reveals
which main histological features impact a patient’s outcome. Some of the findings of our
study will guide future research to develop new therapies for this “orphan” disease that
urgently need new approaches. For instance, the finding that PMN infiltration is associated
with a more favorable outcome shifts the paradigm in the field of alcoholic hepatitis (AH)
and suggests that patients with active inflammation probably have more regenerative
potential and are more likely to survive to the episode of AH. Attempts to improve liver
regeneration, rather than blocking inflammation, seem more appropriate for this patient
population.
Finally, we acknowledge the exclusion of patients without histological criteria of alcoholic
steatohepatitis (n=34). Unfortunately, this drawback was due to protocol reasons. The
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prognostic capability of the AHHS in these patients and whether this subset of patients had a
more favorable outcome is extremely interesting and deserves future investigation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Histological Features Independently Associated with 90-day Survival Included in the
Alcoholic Hepatitis Histological Score (AHHS). A, B and C) Degree of fibrosis (Masson’s
Trichrome staining); portal fibrosis, expansive areas of liver fibrosis and cirrhosis,
respectively. Photomicrographs A, B and C: Hematoxylin and eosin staining.
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Figure 2.
Histological Features Independently Associated with 90-day Survival Included in the
Alcoholic Hepatitis Histological Score (AHHS). A) Hepatocellular and canalicular
bilirubinostasis (arrow). B) Ductular bilirubinostasis (arrow). C) Megamitochondria
(arrows). D and E) Mild and severe PMN infiltration, respectively. Photomicrographs A–D
and E: Hematoxylin and eosin staining; PNM: Polymorphonuclear cells.
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Figure 3.
Three-month Survival Probability of Patients with Alcoholic Hepatitis According to the
Alcoholic Hepatitis Histological Score (AHHS) in the study (a) and validation (b) cohorts.
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Figure 4.
a) Three-month survival probability in patients with ABIC B according to the Alcoholic
Hepatitis Histological Score. a) Three-month survival probability in patients with MELD
<21 according to the Alcoholic Hepatitis Histological Score
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Table 1
Baseline Demographic, Clinical, Hemodynamic and Histological Characteristics of Patients with Alcoholic
Hepatitis in the Training Cohort (n=121)
Characteristics Median (25–75 IQR)
Age (y) 49 (41–54)
Male n (%) 78 (67)
Alcohol intake (g/day) 100 (100–120)
Corticosteroids n (%) 54 (45)
Biopsy Length (cm) 0.6 (0.4–1.2)
Clinical decompensations at admission
 Ascites n (%) 82 (68)
 Variceal bleeding n (%) 26 (21)
 Encephalopathy n (%) 17 (14)
 Infection n (%) 18 (15)
Laboratory and hemodynamic parameters
 Hemoglobin (g/dL) 11 (9–12)
 Leukocyte count ×109/L 8.9 (6.3–13.9)
 Platelet count ×109/L 121 (71–175)
 AST (U/L) 125 (82–188)
 ALT (U/L) 51 (35–71)
 Serum Na (mmol/L) 134 (130–137)
 Serum albumin (g/dL) 2.7 (2.3–3.0)
 Serum creatinine (mg/dL) 0.8 (0.60–1.0)
 Serum bilirubin (mg/dL) 9.7 (4.3–17.7)
 International normalized ratio 1.6 (1.4–1.9)
 HVPG (mmHg)* 20 (15–24)
Alcoholic hepatitis severity scores at admission
 MELD score 18 (12–22)
 ABIC score 7.3 (6.6–8.4)
 ABIC class n(%)
  A (<6.71) 33 (27)
  B (6.7–8.99) 68 (56)
  C (≥9) 20 (17)
Histological features at admission n (%)
Fibrosis stage
 No Fibrosis or Portal fibrosis 3 (2)
 Expansive fibrosis 19 (16)
 Bridging fibrosis or Cirrhosis 99 (82)
Steatosis
 <33% 39 (32)
 33–66% 35 (29)
 >66% 47 (39)
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Characteristics Median (25–75 IQR)
Mallory bodies
 No or Occasional 4 (3)
 Marked 117 (97)
Bilirubinostasis
 No 37 (31)
 Hepatocellular 14 (12)
 Canalicular and/or ductular 32 (26)
 Hepatocellular plus canalicular and/or ductular 38 (31)
Ballooning
 Occasional 48 (40)
 Marked 73 (60)
PMN infiltration
 No/Mild 81 (67)
 Severe 40 (33)
Megamitochondria
 No 30 (25)
 Yes 91 (75)
Abbreviations: IQR, interquartile range; AST, aspartate aminotransferase level; ALT, alanine aminotransferase level; HVPG, hepatic venous
pressure gradient; MELD, model for end-stage liver disease; ABIC, age-bilirubin-INR-creatinine score; PMN, polymorphonuclears
*
Data from 112 patients
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Table 3
Alcoholic Hepatitis Histological Score (AHHS) for Prognostic Stratification of Alcoholic Hepatitis
Points
Fibrosis stage AHHS categories (0–9 points)
 None Fibrosis or Portal fibrosis 0 Mild : 0–3
 Expansive fibrosis 0 Intermediate: 4–5
 Bridging fibrosis or Cirrhosis +3 Severe: 6–9
Bilirubinostasis
 No 0
 Hepatocellular only 0
 Canalicular or ductular +1
 Canalicular or ductular plus Hepatocellular +2
PMN infiltration
 No/Mild +2
 Severe PMN Infiltration 0
Megamitochondria
 No Megamitochondria +2
 Megamitochondria 0
Abreviations: PMN: polymorphonuclears.
Note: Histological features included in the AHHS where product of the multivariate logistic regression analysis (Table 2). Weighting of each
histological feature was based in the odds ratio of the updated model (training plus test set samples. See model building in Supplementary Data).
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